You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Cetuximab, Paclitaxel, Carboplatin, and Radiation for Head and Neck Cancer: A Survival Analysis of a Brown University Oncology Group Phase II Study

Birnbaum, Ariel MD; Dipetrillo, Thomas MD; Rathore, Ritesh MD; Merriam, Priscilla MD; Wanebo, Harry MD; Thomas, Anthony MD; Puthawala, Yacoub MD; Joyce, Donald MD; Luppe, Denise RN; Khurshid, Humera MD; Follett, Nancy RN; Sio, Terence Tai-Weng MD; Safran, Howard MD

American Journal of Clinical Oncology:
doi: 10.1097/COC.0b013e31826e06e0
Original Articles: Head & Neck

Objectives: To assess the effect on progression-free and overall survival from the addition of cetuximab to paclitaxel-based chemoradiation for patients with squamous cell head and neck cancer from Brown University Oncology Group studies.

Methods: BrUOG HN-204 patients with stage III or IV locally advanced squamous cell cancer of the head and neck without distant organ metastases received 4 weeks of induction cetuximab followed by weekly cetuximab, paclitaxel, carboplatin, and concurrent radiation. Recurrence and survival data were compared with previous Brown University studies utilizing the same paclitaxel-based chemoradiation with and without induction chemotherapy.

Results: The progression-free survival and overall survival at 3 years for all 37 patients initiating chemoradiation was 54% and 57%, respectively. All surviving patients were followed for at least 3 years and the median follow-up is 4.4 years. Of 14 patients who recurred within 3 years, 7 patients recurred locally only, 5 had a systemic recurrence, and 2 recurred both locally and systemically.

Conclusions: The addition of cetuximab to paclitaxel, carboplatin, and radiation achieves overall survival that is virtually identical to prior Brown University Oncology Group studies of paclitaxel-based chemoradiation without cetuximab. Improvements in locoregional control are needed despite the use of 3 agents to enhance the effects of radiation.

Author Information

Brown University Oncology Group, Providence, RI

Supported by Bristol-Myers Squibb.

The authors declare no conflicts of interest.

Reprints: Howard Safran MD, Brown University Oncology Group, 97 Waterman Street, P.O. Box G-A 418, Providence, RI 02912. E-mail:

© 2014 by Lippincott Williams & Wilkins, Inc